Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1393 - Clinical study of Apatinib in the treatment of malignant pleural effusion and malignant celiac effusion

Date

11 Sep 2017

Session

Poster display session

Topics

Clinical Research

Presenters

Ma Xin

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

M. Xin

Author affiliations

  • Radiotherapy Department, 4th Hospital Medical University, 5001 - Shijiazhuang/CN
More

Resources

Abstract 1393

Background

Malignant pleural effusion and malignant celiac effusion is a severe complication of the advanced malignant tumor, The formation of malignant pleural effusion and malignant celiac effusion relied on VEGF growth factor.Apatinib blocking vascular endothelial growth factor (VEGF) combining with the receptor and blocking signal transduction pathway, thereby inhibiting tumor and the formation of new blood vessels, inhibit the formation of the malignant pleural effusion and malignant celiac effusion. We conducted the study to exploring the single-agent oral path of Apatinib for the treatment of malignant pleural effusion and malignant celiac effusion of the clinical curative effect.

Methods

Patients were eligible for inclusion in the study if they had histologically confirmed malignancies, with malignant pleural effusion and malignant celiac effusion. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Study Objective: Clinical curative effect. Study Design and Treatment: This study recruited 13 patients with histologically confirmed malignancies, and the patients with malignant pleural effusion and malignant celiac effusion from January 2016 to October 2016. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. All patients were given the oral drug Apatinib, the doses of oral given is 500 mg or 425 mg everyday until progressive disease (PD) or intolerable toxicity. Assessment and Statistical analysis: The assessmet were determined according to the World Health Organization (WHO) criteria. The ORR and DCR analyses were based on frequencies.

Results

Table:

381P Baseline patient characteristics

Characteristic Apatinib(n = 13)
Age(years)Median(range) 58(44-84) Sex Male 7(53.85) Female 6(46.15) EGOG PS 0 2(15.38) 1 6(46.15) 2 5(38.46) Carcinoma Lung cancer 6(46.15) Pancreatic cancer 4(30.77) Breast cancer 2(15.38) Thymic cancer 1(7.7)
Efficacy: Apatinib is effective for the treatment of malignant pleural effusion and malignant celiac effusion: CR 5 cases, PR 5 cases, SD 3 cases, overall-response rate (ORR)76.92%, disease-control rate (DCR)100%.

Conclusions

Apatinib is a safe, feasible way in the treatment of malignant pleural effusion and malignant celiac effusion. Relying on the simple method and favourable rencent curative effect. Apatinib provides a new way for the treatment of malignant pleural effusion and malignant celiac effusion that deserves further research.

Clinical trial identification

Legal entity responsible for the study

GuoXin Ma

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.